Systematic review of bisphosphonates for hypercalcaemia of malignancy

Palliative Medicine

Volumn 18, Issue 5, 2004, Pages 418-431

  Saunders, Yolandes ^a,d   Ross, J R ^a   Broadley, K E ^a   Edmonds, P M ^b   Patel, S ^c   A'Hern, R ^e   Chinn, R ^e   Dearnaley, D ^e   Dowsett, M ^e   Evans, S ^e   Feuer, D ^e   Hardy, J ^e   Johnston, S ^e   Normand, C ^e   Powles, T ^e   Wonderling, D ^e  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d HILLINGDON HOSPITAL   (United Kingdom)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM ION; CLODRONIC ACID; ELCATONIN; ETIDRONIC ACID; GALLIUM NITRATE; IBANDRONIC ACID; INCADRONIC ACID; MITHRAMYCIN; PAMIDRONIC ACID; PLACEBO; PREDNISOLONE;

CALCIUM BLOOD LEVEL; CANCER; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG TOLERABILITY; HUMAN; HYPERCALCEMIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

DIPHOSPHONATES; HUMANS; HYPERCALCEMIA; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 4444286370     PISSN: 02692163     EISSN: None     Source Type: Journal    
DOI: 10.1191/0269216304pm914ra     Document Type: Review

References (81)

1. Twycross R. Biochemical syndromes. In Twycross R ed. Symptom management in advanced cancer. Oxford: Radcliffe Medical Press, 1997: 132-42.
2. Grill V, Rankin W, Martin TJ. Parathyroid hormone-related protein (PTHrP) and hypercalcaemia. Eur J Cancer 1998; 34: 222-29.
3. Wimalawansa SJ. Significance of plasma PTH-rP in patients with hypercalcemia of malignancy treated with bisphosphonate. Cancer 1994; 73: 2223-30.
4. Mundy GR. Hypercalcaemia associated with hematologic malignancies. In Mundy GR ed. Calcium homeostasis. hypercalcaemia and hypocalcaemia. London: Martin Dunitz, 1990: 100-15.
5. Grill V, Martin TJ. Hypercalcaemia of malignancy. Rev Endocr Metab Disord 2001; 1: 253-63.
6. Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 1999; 21: 389-406.
7. Siggaard-Andersen O, Thode J, Fogh-Andersen N. What is 'ionized calcium'? Scand J Clin Lab Invest 1983; 43: 11-15.
8. Kanis JA, Yates AJ. Measuring serum calcium. BMJ 1985; 290: 728-29.
9. Berry EM, Gupta MM, Turner SJ, et al. Variation in plasma calcium with induced changes in plasma specific gravity, total protein and albumin. BMJ 1973; 4: 640-43.
10. Payne R. Interpretation of serum calcium in patients with abnormal serum proteins. BMJ 1973; 4: 643-46.
11. Bajorunas DR. Clinical manifestations of cancer related hypercalcaemia. Semin Oncol 1990; 17: 16-25.
12. Bilezikian JP. Management of acute hypercalcaemia. N Engl J Med 1992; 326: 1196-203.
13. Kristensen B, Ejlertsen B, Mouridsen HT, et al. Survival in breast cancer patients after the first episode of hypercalcaemia. J Intern Med 1998; 244: 189-98.
14. Chisholm MA, Malloy AL, Taylor AT. Acute management of cancer related hypercalcaemia. Ann Pharmacother 1996; 30: 507-13.
15. Wineski LA. Salmon calcitonin in the acute management of hypercalcaemia. Calcif Tissue Int 1990; Suppl 46: S26-S30.
16. Warrell RP, Israel R, Frisone M, et al. Gallium nitrate for acute treatment of cancer related hypercalcaemia. Ann Intern Med 1988; 108: 669-74.
17. Harrison M, James N, Broadley K, et al. Somatostatin analogue treatment for malignant hypercalcaemia. BMJ 1990; 300: 1313-14.
18. Fleisch H. Bisphosphonates: mechanism of action. Endocr Rev 1998; 9: 80-100.
19. Russell RG, Rogers M, Frith JC, et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res 1999; 14: 53-65.
20. Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonate inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13: 581-89.
21. Coxon FP, Helfrich MH, Van't Hof R, et al. Protein geranylgeranylation is required for osteoclast formation, function and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000; 15: 1467-76.
22. Rogers MJ, Frith JC, Luckman SP, et al. Molecular mechanisms of action of bisphosphonates. Bone 1999; 24: 73s-79s.
23. Fleisch H. Bisphosphonates: pharmacology and use in the treatment of tumour induced hypercalcaemic and metastatic bone disease. Drugs 1991; 42: 919-44.
24. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994; 309: 1286-91.
25. Selection bias. Cochrane reviewers handbook 6.3 [updated June 2001]. In Clarke M, Oxman AD eds. The Cochrane Library, Issue 3. Oxford: Update Software. Updated quarterly, 2001.
26. Statacorp. Stata statistical software: Release 7.0. College Station, TX, USA: STATA Corporation, 2001.
27. Hasling C, Charles P, Mosekilde L. Etidronate disodium in the management of malignancy-related hypercalcemia. Am J Med 1987; 82: 51-54.
28. Vinholes J, Guo CY, Purohit OP, et al. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. J Clin Oncol 1997; 15: 131-38.
29. Wimalawansa SJ. Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy. Clin Endocrinol 1994; 41: 591-95.
30. Rizzoli R, Buchs B, Bonjour JP. Effect of a single infusion of alendronate in malignant hypercalcaemia: dose dependency and comparison with clodronate. Int J Cancer 1992; 50: 706-12.
31. Atula ST, Tahtela RK, Nevalainen JI, et al. Clodronate as a single-dose intravenous infusion effectively provides short-term correction of malignant hypercalcaemia. Acta Oncol 2003; 42: 735-40.
32. Pecherstorfer M, Steinhauer EU, Rizzoli R, et al. Efficacy and safety of ibandronate in the treatment of hypercalcaemia of malignancy: a randomised multicentric comparison to pamidronate. Support Care Cancer 2003; 11: 539-47.
33. Matsumoto T, Nagata N, Horikoshi N, et al. Comparative study of incadronate and elcatonin in patients with malignancy-associated hypercalcaemia. J Int Med Res 2002; 30: 230-43.
34. Gucalp R, Theriault R, Gill I, et al. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. Arch Intern Med 1994; 154: 1935-44.
35. Ostenstad B, Andersen OK. Disodium pamidronate versus mithramycin in the management of tumour-associated hypercalcemia. Acta Oncol 1992; 31: 861-64.
36. Gucalp R, Ritch P, Wiernik PH, et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 1992; 10: 134-42.
37. Ralston SH, Gallacher SJ, Patel U, et al. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet 1989; 2: 1180-82.
38. Purohit OP, Radstone CR, Anthony C, et al. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 1995; 72: 1289-93.
39. Hasling C, Charles P, Mosekilde L. Etidronate disodium for treating hypercalcaemia of malignancy: a double blind, placebo-controlled study. Eur J Clin Invest 1986; 16: 433-37.
40. Warrell RPJ, Murphy WK, Schulman P, et al. A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia. J Clin Oncol 1991; 9: 1467-75.
41. Rotstein S, Glas U, Eriksson M, et al. Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases - a prospective randomised placebo-controlled multicentre study. Eur J Cancer 1992; 28A: 890-93.
42. Warrell R, Mullane M, Bilezikian J, et al. Treatment of cancer associated hypercalcaemia with alendronate sodium: a randomised double-blind comparison with etidronate. Proc Annu Meet Am Soc Clin Oncol 1997.
43. Davis JR, Heath DA. Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcaemia of malignancy. Br J Clin Pharmacol 1989; 28: 269-74.
44. Gallacher SJ, Ralston SH, Fraser WD, et al. A comparison of low versus high dose pamidronate in cancer-associated hypercalcemia. Bone Miner 1991; 15: 249-56.
45. Body JJ, Magritte A, Seraj F, et al. Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions. J Bone Miner Res 1989; 4: 923-28.
46. Nussbaum SR, Younger J, Vandepol CJ, et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med 1993; 95: 297-304.
47. Pecherstorfer M, Herrmann Z, Body JJ, et al. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 1996; 14: 268-76.
48. Ralston SH, Thiebaud D, Herrmann Z, et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcemia. Br J Cancer 1987; 75: 295-300.
49. Nussbaum SR, Warrell RP, Jr., Rude R, et al. Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. J Clin Oncol 1993; 11: 1618-23.
50. Fukumoto S, Matsumoto T, Takebe K, et al. Treatment of malignancy-associated hypercalcemia with YM175, a new bisphosphonate: elevated threshold for parathyroid hormone secretion in hypercalcemic patients. J Clin Endocrinol Metab 1994; 79: 165-70.
51. Dodwell DJ, Howell A, Morton AR, et al. Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia. Postgrad Med J 1992; 68: 434-39.
52. Morton AR, Cantrill JA, Craig AE, et al. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy. BMJ 1988; 296: 811-14.
53. Sawyer N, Newstead C, Drummond A, et al. Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia. Bone Miner 1990; 9: 121-28.
54. Zysset E, Ammann P, Jenzer A, et al. Comparison of a rapid (2-h) versus a slow (24-h) infusion of alendronate in the treatment of hypercalcemia of malignancy. Bone Miner 1992; 18: 237-49.
55. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcaemia of malignancy: a pooled analysis of two randomised, controlled clinical trials. J Clin Oncol 2001; 19: 558-67.
56. Pecherstorfer M, Steinhauer EU, Pawsey S. Ibandronic acid is more effective than pamidronate in lowering serum calcium in patients with severe hypercalcaemia of malignancy (HCM) and has at least equal efficacy to pamidronate in HCM patients with lower baseline calciums. Results of a randomised, open-label, comparative study. Proc Am Soc Clin Oncol 2001; 20: abstract 1535.
57. Atula S, Tahtela R, Nevalainen J, et al. Single IV infusion of clodronate 1500mg is effective in the treatment of hypercalcaemia of malignancy. Eur J Cancer 2001; 37: S354.
58. Unpublished data. Personal communication from Dr S Pawsey, Roche Pharmaceuticals, to Dr JR Ross and Dr Y Saunders; 2001.
59. Baxter C, Jamal H, Cheung J. Differential response to bisphosphonates in a patient with malignant hypercalcaemia. Personal communication to Dr JR Ross and Dr Y Saunders. 2001.
60. Joshua F, Epstein M, Major G. Bisphosphonate resistance in Paget's disease. Bone 2000; 27: 24S.
61. Gurney H, Grill V, Martin TJ. Parathyroid hormone related protein and response to pamidronate in tumor induced hypercalcaemia. Lancet 1993; 341: 1611-13.
62. Walls J, Ratcliffe WA, Howell A, et al. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein. Br J Cancer 1994; 70: 169-72.
63. Kukreja SC, Shevrin DH, Wimbiscus SA, et al. Antibodies to parathyroid hormone related protein lower serum calcium in athymic mouse models of malignancy associated hypercalcaemia due to human tumours. J Clin Invest 1988; 82: 1798-802.
64. Bayne MC, Illidge TM. Hypercalcaemia, parathyroid hormone-related protein and malignancy. Clin Oncol 2001; 13: 377.
65. Rizzoli R, Thiebaud D, Bundred N, et al. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy. J Clin Endocrinol Metab 1999; 84: 3545-50.
66. Bertheault-Cvitkovic F, Tubiana-Hulin M, Chevalier B, et al. Gallium nitrate (GN) versus pamidronate (APD) for acute control of cancer-related hypercalcaemia (CRH): interim results of a randomised double-blind multi-national study (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1995; 14: A369.
67. Ralston SH, Gardner MD, Dryburgh FJ, et al. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia. Lancet 1985; 2: 907-10.
68. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998; 16: 593-602.
69. Canfield RE, Siris ES, Jacobs TP. Dichloromethylene diphosphonate action in hematologic and other malignancies. Bone 1987; 8: s57-62.
70. Chapuy MC, Meunier PJ, Alexandre CM, et al. Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases. J Clin Invest 1980; 65: 1243-47.
71. Daragon A, Peyron R, Serrurier D, et al. Treatment of hypercalcemia of malignancy with intravenous aminohydroxypropylidene bisphosphonate. Results of a stratified, double-blind, randomized two-month dose-response study. Curr Ther Res Clin Exp 1991; 50: 10-21.
72. Delmas P, Chapuy MC, Vignon E, et al. Dichloromethylene diphosphonate (C12MDP) treatment of hypercalcaemia produced from bone metastases. Nouv Presse Med 1982; 11: 1471-74.
73. Jung A, Chantraine A, Donath A, et al. Use of dichloromethylene diphosphonate in metastatic bone disease. N Engl J Med 1983; 308: 1499-501.
74. Martinez ME, Pastrana P, Sanchez-Cabezudo MJ, et al. Effect of clodronate on calcidiol serum levels in women with breast cancer. Calcif Tissue Int 1997; 61: 148-50.
75. Mundy GR, Wilkinson R, Heath DA. Comparative study of available medical therapy for hypercalcemia of malignancy. Am J Med 1983; 74: 421-32.
76. Murray R, Pitt P, Jerums G. A randomised trial of varying doses of aminhydroxypropylidene bisphosphonate (APD) in the treatment of hypercalcaemia of malignancy. Clin Oncol Soc Aust 1990; Seventeenth annual scientific meeting: IS28.
77. Ralston SH, Alzaid AA, Gallacher SJ, et al. Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcaemia. Q J Med 1988; 68: 825-34.
78. Singer FR, Ritch PS, Lad TE, et al. Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. Arch Intern Med 1991; 151: 471-76.
79. Siris ES, Hyman GA, Canfield RE. Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton. Am J Med 1983; 74: 401-406.
80. Thurlimann B, Waldburger R, Senn HJ, et al. Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial. Ann Oncol 1992; 3: 619-23.
81. Witte RS, Koeller J, Davis TE, et al. Clodronate. A randomized study in the treatment of cancer-related hypercalcemia. Arch Intern Med 1987; 147: 937-39.